Sometime later today the FDA is expected to render their decision for the oral version of semaglutide, the first orally delivered GLP-1. We anticipate a positive decision from the FDA which should come as welcome news to Novo Nordisk as they have pretty much bet the farm on this drug. Analysts continue to believe this drug has blockbuster potential and have already begun speculating how it’s approval will impact other oral diabetes therapies.
Just as refresher our position on the drug is also simple as we believe the drug will get off to a strong start once approved . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.